Core Insights - Synaptogenix, Inc. has announced a collaboration with LSU Health New Orleans for preclinical testing of its polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI) [3] - The company has received a new patent for its PUFA analogs, which are aimed at treating neurodegenerative diseases [3][8] - The PUFA analogs are designed to activate the enzyme PKC epsilon (PKC ε), which has shown potential in preclinical models for addressing various neurodegenerative diseases [5] Company Overview - Synaptogenix is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease and Fragile X syndrome [10] - The company holds exclusive rights to its PUFA analogs through a licensing agreement with Cognitive Research Enterprises, Inc. [4] - Bryostatin-1, another therapeutic candidate from Synaptogenix, has undergone testing in over 1,500 individuals in cancer studies, providing a substantial safety database [10] Research and Development - The collaboration with LSU Health New Orleans aims to compare the efficacy of PUFA analogs with Bryostatin in treating spinal cord injury [3] - Previous preclinical testing indicated that PUFA analogs could slow or reverse neurodegenerative processes in Alzheimer's disease and promote synaptogenesis [9] - The company is developing and patenting this class of compounds as next-generation treatments for neurodegenerative diseases [9]
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury